Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (5): 765-769    DOI: 10.12892/ejgo4561.2019
Original Research Previous articles | Next articles
Novel CARD14 mutations in Chinese samples with ovarian endometriosis
J.-Y. Zhou1, 2, 3, Y. Zou2, L.-Q. Wang2, 3, S.-F. Fang2, 3, Y. Luo2, Q.-H. Xie2, F. Wang2, O.-P. Huang1, 2, 3, *()
1College of Medicine, Nanchang University, Nanchang, Jiangxi, China
2Key Laboratory of women's Reproductive Health of Jiangxi Province, Nanchang, Jiangxi, China
3Department of Gynecology, Jiangxi Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi, China
Download:  PDF(608KB)  ( 221 ) Full text   ( 3 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Objectives: Endometriosis is a potential pre-malignant gynecological condition harboring multiple gene mutations in the endometriotic lesions. Evidence has implicated the possibility that caspase recruitment domain family member 14 (CARD14) mutations might exist in ovarian endometriosis. It is questioned whether ovarian endometriosis harbors CARD14 mutations. Materials and Methods: The authors recruited and analyzed a cohort of 101 ovarian endometriosis samples for the presence of CARD14 mutations via sequenced the coding and intron/exon boundary regions of the CARD14 gene. Results: A novel heterozygous somatic CARD14 mutation, p.R470C (c.1408C>T), was identified in two out of 101 (2.0%) endometriotic lesions. The mutated samples were 30-and 31-years-old and both had a history of childbirth. No CARD14 mutations were detected in the remaining 99 samples with ovarian endometriosis. Protein structure modeling results showed CARD14 p.R470C mutation resulted in protein structural changes. These combined results implicated that this mutation might be damaging. However, no association was observed between the main clinical features and CARD14 mutations in this sample cohort. Conclusion: The authors identified a potential damaging CARD14 somatic mutation in 2/101 (2.0%) endometriotic lesions with ovarian endometriosis for the first time, and this mutation might play an active role in the development of ovarian endometriosis.

Key words:  CARD14      Mutation      Ovarian endometriosis      Chinese     
Published:  10 October 2019     
*Corresponding Author(s):  O.-P. HUANG     E-mail:  jxfbhop59@126.com

Cite this article: 

J.-Y. Zhou, Y. Zou, L.-Q. Wang, S.-F. Fang, Y. Luo, Q.-H. Xie, F. Wang, O.-P. Huang. Novel CARD14 mutations in Chinese samples with ovarian endometriosis. European Journal of Gynaecological Oncology, 2019, 40(5): 765-769.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4561.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I5/765

[1] Ji Geun Yoo, Hae Nam Lee, Sung Jong Lee, Jin Hwi Kim, Yong Seok Lee, Ahwon Lee, Soo Young Hur, Keun Ho Lee. Germline BRCA2 mutation is associated with greater progression-free survival in korean women with advanced high-grade serous ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 675-680.
[2] A. Markowska, W. Bednarek, R. Jach, A. Czekała, J. Markowska. Uterine fibroids: a new insight into an old problem[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 915-918.
[3] J. Markowska, E. Nowak-Markwitz, Z. Kojs, W. Sawicki. Considerations related to radical fimbriectomy as an option in prophylaxis against serous carcinoma development[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 709-710.
[4] G. Scandurra, S. Gieri, F. Marletta, B. Pecorino, S. Nicolini, G. L. Banna, G. Scibilia, P. Scollo. Safety and efficacy of new techniques of radiotherapy in oligometastatic recurrent ovarian cancer patients with BRCA1/2 mutation[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 739-743.
[5] A. Markowska, M. Bocianowska, J. Markowska. Molecular factors in endometrial cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 190-192.
[6] Ye Yang, Xiaowei Xi. ARID1A mutation in endometrial cancer: a review[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 705-709.
[7] J G. Artioli, J. Wabersich, L. Borgato, G. Azzarello. Why tube fimbria-end is the favorite site of carcinogenesis in hereditary ovarian cancer? A review of literature and our institution experience[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 381-385.
[8] Y.C. Jang, S.J. Liang. Vaginal primary malignant melanoma of a Chinese woman: an exceptionally rare yet lethal case report and literature review[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 327-330.
[9] Dan Sun, Yu-Juan Fan, Yu-Mei Chen, Jiang-Tao Fan, Hong Chen, Shou-Jun Liang, Ya-Qing Meng. BRCA1 single nucleotide polymorphisms and microsatellite instability in endometrial cancer and their association with patient prognosis in a Chinese population[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 871-877.
[10] D. Wu, K-Y. Wang, C-N. He, H-J. Huang. Association of myeloperoxidase -463G>A polymorphism with cervical cancer in Chinese Han women[J]. European Journal of Gynaecological Oncology, 2017, 38(5): 756-759.
[11] A. Markowska, J. Lubin, J. Markowska, B. Kasprzak, M. Chajewska-Czekańska, R. Mądry, M. Stawicka. Multiple primary cancers in BRCA1/2 carriers – A review of literature and our observations[J]. European Journal of Gynaecological Oncology, 2017, 38(3): 361-363.
[12] H. Yoshida, D. Shintani, Y. Imai, K. Fujiwara. Serous tubal intraepithelial carcinoma arising from the intrauterine portion of the fallopian tube after bilateral salpingo-oophorectomy[J]. European Journal of Gynaecological Oncology, 2016, 37(3): 404-406.
[13] X.P. Chen, W.H. Xu, D.F. Xu, S.M. Fu, Z.C. Ma. G12V Kras mutations in cervical cancer under virtual microscope of molecular dynamics simulations[J]. European Journal of Gynaecological Oncology, 2016, 37(1): 69-74.
[14] X. Ma, Y. Hui, L. Lin, Y. Wu, X. Zhang, X. Qin. Possible relevance of tumor-related genes mutation to malignant transformation of endometriosis[J]. European Journal of Gynaecological Oncology, 2016, 37(1): 89-94.
No Suggested Reading articles found!